35 minute read
Scientific Sessions
Each scientific session presents a group of abstracts covering a similar topic. You'll hear a total of five abstracts presented during each session with interactive audience Q&A after the second and fifth abstracts are presented.
Saturday, April 17, 2021
S1 Epilepsy and Clinical
Neurophysiology (EEG) 1
CME 1
2:00 p.m. ET S1.001
Fetal Antiseizure Medication Effects on Neuropsychological Outcomes at Age 3 Years in the MONEAD Study—Kimford J. Meador, Morris Cohen, David W. Loring, Carrie Brown, Chelsea Robalino, Page B. Pennell
2:08 p.m. ET S1.002
Efficacy of Cenobamate for Uncontrolled Focal Seizures: Post-hoc Analysis of a Phase 3, Multicenter, Open-Label Study—Michael R. Sperling, Bassel W. Abou-Khalil, Sami M. Aboumatar, Perminder JS Bhatia, Victor Biton, Pavel Klein, Gregory L. Krauss, David G. Vossler, Robert T. Wechsler, Louis Ferrari, Marc Kamin, Mindy Grall, William E. Rosenfeld
2:16 p.m. ET
Questions and Answers
2:24 p.m. ET S1.003
Cenobamate Trough Plasma Concentrations in Patients With Uncontrolled Focal Seizures Achieving 50% and 100% Seizure Reduction in Two Randomized Clinical Studies—Stephen Greene, Marc Kamin
2:32 p.m. ET S1.004
HMGB1 as a Therapeutic Target of Focal Cortical Dysplasia—Yang Zheng, Yi Wang, MeiPing Ding, Zhong Chen
2:40 p.m. ET S1.005
Efficacy, Safety, and Tolerability of Soticlestat (TAK-935/OV935) as Adjunctive Therapy in Pediatric Patients with Dravet Syndrome and Lennox-Gastaut Syndrome (ELEKTRA)—Cecil D. Hahn, Yuwu Jiang, Vicente Villanueva, Marta Zolnowska, Dimitrios Arkilo, Peter B. Forgacs, Mahnaz Asgharnejad, Ying Yan, Dennis J. Dlugos
2:48 p.m. ET
Questions and Answers
S2 Advances in MS Imaging
CME 1
2:00 p.m. ET S2.001
Neurite Density Explains Cortical T1-/T2Weighted Ratio in Multiple Sclerosis—Paolo Preziosa, Piet Bouman, Svenja Kiljan, Martijn D Steenwijk, Alessandro Meani, Petra Pouwels, Maria Assunta Rocca, Massimo Filippi, Jeroen JG Geurts, Laura Jonkman
2:08 p.m. ET S2.002
The Importance of Neuroradiology Input at a Neuroinflammatory Multidisciplinary Team (MDT) Meeting: Influencing and Optimising the Management of Patients with Multiple Sclerosis—Stephen Ramsay, Robert Spence, Rebecca Robinson, Niamh Turley, Debarata Bhattacharya, Adam Nelson, Peter Flynn, Aidan G. Droogan, Stella Elaine Hughes, Fiona Kennedy, Gavin V. McDonnell
2:16 p.m. ET
Questions and Answers
2:24 p.m. ET S2.003
Relevance of NODDI to Characterise in Vivo the Microstructural Abnormalities of Multiple Sclerosis Cortex and Cortical Lesions: A 3T Study—Paolo Preziosa, Elisabetta Pagani, Raffaello Bonacchi, Laura Cacciaguerra, Massimo Filippi, Maria Assunta Rocca
2:32 p.m. ET S2.004
Vascular Disease Risk Factors in Multiple Sclerosis (MS) is Associated with Brain Adenosine Triphosphate Abnormalities: Dysmetabolism May Drive MS Disease Progression—Vijayshree Yadav, Michael Lane, Allison Fryman, Manoj K. Sammi
2:40 p.m. ET S2.005
Choroid Plexus Enlargement Characterizes Inflammatory Multiple Sclerosis—Vito Antonio Gerardo Ricigliano, Emanuele Morena, Annalisa Colombi, Matteo Tonietto, Mariem Hamzaoui, Emilie Poirion, Michel Bottlaender, Celine Louapre, Benedetta Bodini, Bruno Stankoff
2:48 p.m. ET
Questions and Answers
S3 Movement Disorders 1
CME 1
2:00 p.m. ET S3.001
Understanding the Natural History of SCA2, SCA3, and SCA10 Through Clinical Scales— Marise Zonta, Helio Afonso Ghizoni Teive, Carlos Henrique Ferreira Camargo, Alex Meira, Francisco Diego Negr Neto, Fernando Spina Tensini, Tetsuo Ashizawa, Renato Puppi Munhoz
2:08 p.m. ET S3.002
Analysis of 96-Week, Long-Term Open Label Extension Phase of Study BHV4157-201: A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Troriluzole in Adult Subjects with Spinocerebellar Ataxia—Melissa Beiner, Victoria Wirtz, Gilbert J. L'Italien, Laura Ruggiero, Robert Berman, Vlad Coric
2:16 p.m. ET
Questions and Answers
2:24 p.m. ET S3.003
The Role of the Cerebellum in Tremor-dominant Cervical Dystonia—Abhimanyu Mahajan, Lyndsey Schroder, Aleksander Rekhtman, Alok Dwivedi, Lily Wang, Alberto J. Espay
2:32 p.m. ET S3.004
PD GENEration: Feasibility and Impact of Providing In-Person Versus Remote Genetic Testing and Counseling for People with Parkinson’s Disease—Jennifer Verbrugge, Lola Shukla, Jeanine Schulze, Tae-Hwi Schwantes-An, James Beck, Anna Naito, Anne Hall, Karen S. Marder, Martha A. Nance, Michael Schwarzschild, Tanya Simuni, Hector M. Gonzalez, Roy Alcalay
2:40 p.m. ET S3.005
Efficacy and Safety of SEP-363856, a Non–D2Receptor Binding Drug With Antipsychotic Activity, in Patients With Parkinson’s Disease Psychosis—Stuart H. Isaacson, Mark A. Goldstein, Rajesh Pahwa, Carlos Singer, Kevin J. Klos, Ian Zhang, David Crandall, Bradford Navia
2:48 p.m. ET
Questions and Answers
S4 Child Neurology and
Developmental Neurology
CME 1
4:00 p.m. ET S4.001
Onasemnogene Abeparvovec Gene Therapy in Presymptomatic Spinal Muscular Atrophy (SMA): SPR1NT Study Update in Children with 3 Copies of SMN2—Kevin Strauss, Francesco Muntoni, Michelle A. Farrar, Kyoko Saito, Jerry R. Mendell, Laurent Servais, Hugh John McMillan, Kathryn J. Swoboda, Jennifer M. Kwon, Craig M. Zaidman, Claudia A. Chiriboga, Susan T. Iannaccone, Jena M. Krueger, Julie Anne Parsons, Perry Shieh, Sarah Kavanagh, Deepa Chand, Sitra TauscherWisniewski, Thomas Macek
4:08 p.m. ET S4.002
ASPIRO Gene Therapy Trial In X-Linked Myotubular Myopathy (XLMTM): Update on Preliminary Efficacy and Safety Findings—Perry Shieh, Nancy L. Kuntz, James Dowling, Wolfgang Mueller-Felber, Astrid Blaschek, Carsten G. Bonnemann, A. Reghan Foley, Dimah N. Saade, Andreea Mihaela Seferian, Laurent Servais, Michael W Lawlor, Mojtaba Noursalehi, Suyash Prasad, Salvador Rico, Weston Miller
4:16 p.m. ET
Questions and Answers
4:24 p.m. ET S4.003
The RIKEE database: Genotype-Phenotype Patterns in KCNQ Channel Related Disease, Based on 784 Individuals and Pedigrees— Edward C. Cooper, John J. Millichap, Tammy Tsuchida, Maurizio Taglialatela, Sarah Weckhuysen
4:32 p.m. ET S4.004
Improving Triaging of EEG Referrals for Rule out Infantile Spasms (ITERIS)—Djurdja Djordjevic, Jennifer Tracey, Cristina Y. Go
4:40 p.m. ET S4.005
Long-Term Follow-Up (LTFU) of Onasemnogene Abeparvovec Gene Therapy in Spinal Muscular Atrophy (SMA)—Jerry R. Mendell, Richard S. Finkel, Eugenio Mercuri, Kevin Strauss, John W. Day, Aaron Kleyn, Deepa Chand, Sitra Tauscher-Wisniewski, Matthew N. Meriggioli
4:48 p.m. ET
Questions and Answers
Saturday, April 17, 2021
S5 Headache 1
CME 1
4:00 p.m. ET S5.001
Long-term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine— Messoud Ashina, Stewart J. Tepper, Uwe Reuter, Andrew M. Blumenfeld, Susan Hutchinson, Jing Xia, Rosa Miceli, Lawrence Severt, Michelle Finnegan, Joel M. Trugman
4:08 p.m. ET S5.002
Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study—Susan Hutchinson, Jack D. Schim, Richard B. Lipton, Robert Croop, Christopher Jensen, Alexandra Thiry, Elyse Stock, Charlie Conway, Meghan Lovegren, Vlad Coric, Michael Hanna
4:16 p.m. ET
Questions and Answers
4:24 p.m. ET S5.003
Intranasal Zavegepant is Effective and Well Tolerated for the Acute Treatment of Migraine: A Phase 2/3 Dose-Ranging Clinical Trial—Robert Croop, Jennifer Madonia, Charlie Conway, Alexandra Thiry, Micaela Forshaw, Abigail Murphy, Christopher Jensen, Gene Dubowchik, Vlad Coric, Richard B. Lipton
4:32 p.m. ET S5.004
Ubrogepant Was Safe and Well Tolerated in the Acute Treatment of Perimenstrual Migraine— Jelena M. Pavlovic, Jessica Ailani, Susan Hutchinson, Jeff Lai, Brett Dabruzzo, Sung Y. Yu, Joel M. Trugman, Anne MacGregor
4:40 p.m. ET S5.005
Real World Efficacy, Tolerability, and Safety of Ubrogepant—Chia-Chun Chiang, Karissa Arca, Rachel Dunn, Marlene Girardo, Jaxon Quillen, David W. Dodick, Amaal J. Starling
4:48 p.m. ET
Questions and Answers
S6 Cerebrovascular Disease and
Interventional Neurology: Acute
Stroke Treatment
CME 1
4:00 p.m. ET S6.001
Prediction of Infarct Volume at the 24 Hours after Late Window Presentation with Perfusion Imaging in Patients with Anterior Circulation Large Vessel Occlusion—Shashank Agarwal, Eytan Raz, Seena Dehkharghani, Soren Christensen, Maarten G. Lansberg, Shadi Yaghi, Adam De Havenon
4:08 p.m. ET S6.002
Current Utilization of Endovascular Mechanical Thrombectomy in the Treatment of Acute Ischemic Stroke in the US—Isobel MacKenzie, Dimitri Sigounas
4:16 p.m. ET
Questions and Answers
4:24 p.m. ET S6.003
Blood Pressure Reductions in the Hyperacute Phase of Large Vessel Occlusion Ischemic Stroke Are Associated With Infarct Progression And Poor Functional Outcome—Krithika Umesh Peshwe, Cindy Khanh Phuong Nguyen, Sreeja Kodali, Jessica Kobsa, Ayush Prasad, Alexandria Soto, Charles R. Wira, Charles Matouk, Kevin N. Sheth, Nils Petersen
4:32 p.m. ET S6.004
Reduction of Door to Groin Puncture Time for Mechanical Thrombectomy After Implementation of Ventura ELVO Score (VES)— Syed A. Quadri, Sajid Suriya, Mudassir Farooqui, Aqsa Baig, Muhammad Taqi
4:40 p.m. ET S6.005
Readmission In Acute Ischemic Stroke Patients Undergoing Endovascular Treatment—Saqib A. Chaudhry, Ibrahim Laleka, Hussan Gill, Mohammad Rauf A. Chaudhry, Ameer Hassan, Haseeb Abdul Rahman, Zelalem Bahiru, Iqra N Akhtar, Sairah Bashir, Jing Wang, Yun Fang, Laith Altaweel, Adnan I. Qureshi
4:48 p.m. ET
Questions and Answers
Sunday, April 18, 2021
S7 Autoimmune and Paraneoplastic
Neurologic Disorders:
Diagnosis, Epidemiology, and
Pathophysiology
CME 1
2:00 p.m. ET S7.001
Population-Based Epidemiology Study of Paraneoplastic Neurological Syndromes— Shailee Samir Shah, Eoin P. Flanagan, Pritikanta Paul, Carin Smith, Sandra Bryant, Andrew McKeon, Sean J. Pittock, Divyanshu Dubey
2:08 p.m. ET S7.002
Thymoma-associated Neuronal Surface Antibodies and Clinical Manifestations—Mar Guasp, Eugenia Martinez-Hernandez, Jon Landa, Lidia Sabater, Albert Saiz, Francesc R. Graus, Josep O. Dalmau
2:16 p.m. ET
Questions and Answers
2:24 p.m. ET S7.003
Anti-Metabotropic Glutamate Receptor (mGluR)1 Encephalitis: Identification Of Prognostic Factors And Study Of Antibody Effects—Marianna Spatola, Mar Petit-Pedrol, Estibaliz Maudes, Mateus Mistieri Simabukuro, Sergio Muniz-Castrillo, Anne-Laurie Pinto, KlausPeter Wandinger, Juliane Spiegler, Peter Schramm, Livia Almeida Dutra Antonio, Raffaele Iorio, Cornelia Kornblum, Romana Hoeftberger, Frank Leypoldt, Maarten Jan Titulaer, Peter Sillevis Smitt, Jerome Honnorat, Myrna R. Rosenfeld, Francesc R. Graus, Josep O. Dalmau
2:32 p.m. ET S7.004
Seizure-related 6 Homolog like 2 (SEZ6L2) Aautoimmunity: Neurologic Syndrome and Antibody Effects—Mar Guasp, Jon Landa, Mar Petit-Pedrol, Eugenia Martinez-Hernandez, Jesus Planaguma, Albert Saiz, Raquel Ruiz-Garcia, Lorena Garcia, Jan Verschuuren, Rachel J. Saunders-Pullman, Liliana A. Ramirez-Gomez, Michael D. Geschwind, Josep O. Dalmau, Lidia Sabater, Francesc R. Graus
2:40 p.m. ET S7.005
The Positive Predictive Value of Aquaporin-4 Antibody Live Cell-based Assay in a Tertiary Referral Center—Mayra Montalvo Perero, Sean J. Pittock, Elia Sechi, James Fryer, Andrew McKeon, John R. Mills, John Chen, Eoin P. Flanagan
2:48 p.m. ET
Questions and Answers
S8 Neuromodulation in Movement
Disorders
CME 1
2:00 p.m. ET S8.001
Electrophysiological Evidence for DBS Influencing Network Versus Individual Neuron Activity in the Subthalamic Nucleus—Ashley C. Guest, Dakota Graham, Margaret Lambert, Holly A. Shill, Francisco Ponce, Bradley Greger
2:08 p.m. ET S8.002
Identifying a Gait Circuit from Focal Stroke Lesions and Deep Brain Stimulation Connectivity in Parkinson’s Disease—Lan Luo, Frederic Schaper, Sandrine Jabbour, Joey Hsu, Louis Soussand, Shan Siddiqi, Andreas Horn, Martin Reich, Jens Volkmann, Andrea Kuehn, Maurizio Corbetta, Michael D. Fox
2:16 p.m. ET
Questions and Answers
2:24 p.m. ET S8.003
10-Year Clinical Outcomes of Subthalamic Nucleus versus Pallidal Deep Brain Stimulation for Parkinson’s Disease: VA/NINDS CSP #468F—Jill L. Ostrem, Ping Luo, Frances Weaver, Kenneth Follett, Nicholas B. Galifianakis, Eugene C. Lai, Jeff M. Bronstein, John E. Duda, Kathryn Holloway, Aliya Sarwar, Matthew A. Brodsky, Kathryn Anne Chung, Meredith Spindler, Domenic Reda, Johannes Rothlind, Amanda Snodgrass, William J. Marks
2:32 p.m. ET S8.004
Long-Term Evaluation of Deep Brain Stimulation for Treatment of Parkinson's Disease Using a Multiple-Source, Constant-Current Rechargeable System: 4-year Follow-Up of a Prospective, Double-Blind RCT—Jerrold L. Vitek, Roshini Jain, Lilly Chen, INTREPID Study Group, Philip Starr
2:40 p.m. ET S8.005
North American Survey on the Effects of the COVID-19 Pandemic Shutdown on DBS Care—Mustafa S. Siddiqui, Sol T. De Jesus, Harini Sarva, James McInerney, Fedor Panov, Michele K. York, Jason Schwalb, Zoltan Mari, Benjamin L. Walter, Joshua M. Rosenow, Neepa J. Patel, John M. Bertoni, Lin Zhang, Joohi Jimenez Shahed
2:48 p.m. ET
Questions and Answers
Sunday, April 18, 2021
S9 Sleep: Highlight Presentations on RBD
CME 1 S10 Epilepsy and Clinical
Neurophysiology (EEG) 2
CME 1
2:00 p.m. ET S9.001
Effects of Solriamfetol on Driving Performance in Participants With Narcolepsy—Frederick Vinckenbosch, Gerrit Jan Lammers, S Overeem, Dan Chen, Grace Wang, LP Carter, Kefei Zhou, Jan Ramaekers, Annemiek Vermeeren
2:08 p.m. ET S9.002
Quality of Life in a Phase 3, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study of Lower-Sodium Oxybate in Adults With Narcolepsy With Cataplexy—Nancy R. FoldvarySchaefer, Michael J. Thorpy, Yves Dauvilliers, Asim Roy, Lihua Tang, Roman Skowronski, Karel Sonka, Richard K. Bogan
2:16 p.m. ET
Questions and Answers
2:24 p.m. ET S9.003
Frequency and Predictors of Obstructive Sleep Apnea in a Cognitively Impaired Clinic Population—David Robert Colelli, Sandra E. Black, Mario Masellis, Benjamin Lam, Andrew Lim, Mark Boulos
2:32 p.m. ET S9.004
Cutaneous Alpha-Synuclein is Correlated with Autonomic Impairment in Isolated REM Sleep Behavior Disorder—Mitchell G. Miglis, Jennifer Zitser-Koren, Sharika Rajan, Emmanuel H. During, Logan D. Schneider, Safwan S. Jaradeh, Roy L. Freeman, Christopher H. Gibbons
2:40 p.m. ET S9.005
Patient Preferences for Prognostic Counseling in Idiopathic/Isolated REM Sleep Behavior Disorder—Thomas Gossard, Luke Teigen, Paul Timm, John Craig Feemster, Stuart McCarter, Erik Kent St. Louis
2:48 p.m. ET
Questions and Answers
4:00 p.m. ET S10.001
Modulation of Resting State Networks by Antiseizure Medications in Patients With Idiopathic Generalized Epilepsy—Juanita Espinosa, Karen Alves, Luiz Eduardo Betting
4:08 p.m. ET S10.002
Functional Connectivity for Disease Classification in Epilepsy: A Machine Learning Approach—Taha Gholipour, Xiaozhen You, Steven Stufflebeam, William D. Gaillard
4:16 p.m. ET
Questions and Answers
4:24 p.m. ET S10.003
Assessment of the Validity of the 2HELPS2B Score for Inpatient Seizure Risk Prediction— Aaron F. Struck, Mohammad Tabaeizadeh Fesharaki, Christa Brittany Swisher, Christian Hernandez, Safa Kaleem, Hiba Arif Haider, Lawrence J. Hirsch, Eric Rosenthal, Sahar Fatima Zafar, M. Brandon Westover
4:32 p.m. ET S10.004
Convulsive Status Epilepticus: Who Dies and Why—Jessica Bloomfield, Fawaz Al-Mufti
4:40 p.m. ET S10.005
A Unique Population Based Epilepsy Network in Ontario Enhances Epilepsy Care and the Availability of Epilepsy Surgery—O. Carter Snead, Elizabeth Donner, Sharon E. Whiting, Tadeu Fantaneanu, Lysa Boisse Lomax, Esther Bui, Danielle M. Andrade, Taufik Valiante, Anastasia Vogt, Kirk Nylen, Rajesh RamachandranNair, Michelle Shapiro, James Rutka, Andrea Andrade, Ayman Emam H. Hassan, Jorge G. Burneo
4:48 p.m. ET
Questions and Answers
S11 MS Immunology and Basic
Science
CME 1
4:00 p.m. ET S11.001
Plasma Neurofilament Light Chain and Glial Fibrillary Acidic Protein Levels Are Prognostic of Disability Worsening: A Biosignature That Helps Differentiating Active From Non-active SPMS—Jens Kuhle, Aleksandra Maleska Maceski, Rolf Meinert, Inga Ludwig, Thomas Hach, Ludwig Kappos, David Leppert, Harald Kropshofer
4:08 p.m. ET S11.002
A Genome-Wide Association Study Highlights a Possible Involvement of Mast Cells and Neutrophils in Disease Activity in Multiple Sclerosis—Antonino Giordano, Melissa Sorosina, Ferdinando Clarelli, Laura Ferre, Silvia Santoro, Elisabetta Mascia, Miryam Cannizzaro, Massimo Filippi, Federica Esposito
4:16 p.m. ET
Questions and Answers
4:24 p.m. ET S11.003
Specific Blockade of Bone Morphogenetic Protein-2/4 induces Oligodendrogenesis and Remyelination in Demyelinating Disorders— Karin Fainberg-Mausner, Moshe Benhamou, Maya Golan, Nadav Bleich Kimelman, Uri Danon, Ehud Marom, Arnon Karni
4:32 p.m. ET S11.004
Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: MAGNIFY-MS Study—Heinz Wiendl, Klaus Schmierer, Suzanne J. Hodgkinson, Tobias Derfuss, Andrew Chan, Finn Sellebjerg, Anat Achiron, Xavier Montalban, Alexandre Prat, Nicola De Stefano, Frederik Barkhof, Letizia M. Leocani, Patrick Vermersch, Anita Chudecka, Sanjeev Roy, Ursula Boschert
4:40 p.m. ET S11.005
ACT-1004-1239, a First-in-class CXCR7 Antagonist with both Immunomodulatory and pPro-myelinating Effects, for the Treatment of Inflammatory Demyelinating Diseases—Laetitia Pouzol, Melanie Tunis, Anna Sassi, Julia Marrie, Enrico Vezzali, Herve Farine, Ulrich Mentzel, Marianne Martinic
4:48 p.m. ET
Questions and Answers
S12 Interventional/Observational
Studies of Neuromuscular
Diseases
CME 1
4:00 p.m. ET S12.001
Long-term Remission with Rituximab in Refractory Generalized Myasthenia Gravis— Juan Ignacio Castiglione, Fabio Adrian Barroso, Patricio Brand, Andrea Lautre, Alejandro Kohler
4:08 p.m. ET S12.002
The Canadian Neuromuscular Disease Registry: A National Spinal Muscular Atrophy (SMA) Registry for Real World Evidence—Maryam Oskoui, Victoria Hodgkinson, Bernard Brais, Craig Gordon Campbell, Joshua Lounsberry, Alex MacKenzie, Hugh John McMillan, Jiri Vajsar, Lawrence Korngut
4:16 p.m. ET
Questions and Answers
4:24 p.m. ET S12.003
Non-dystrophic Myotonia: 2 Year Outcomes of Objective and Patient Reported Outcomes— Timothy R. Fullam, Swathy Chandrashekhar, Constantine Farmakidis, Duaa Jabari, Omar Jawdat, Mamatha Pasnoor, Mazen M. Dimachkie, Jeffrey Statland, CINCH Consortium
4:32 p.m. ET S12.004
SORD Neuropathy: Gene Identification and Proposal for a Follow Up Multi-Centre Natural History Study—Andrea Cortese, Maike Dohrn, Yi Zhu, Adriana Rebelo, Jingyu Wang, Jingyu Wang, Shawna Feely, Valerie Cassucio, Michaela AuerGrumbach, Sherifa Ahmed Hamed, Ruxu Zhang, Fiore Manganelli, Franco Taroni, Davide Pareyson, Henry Houlden, David N. Herrmann, Mary Reilly, Michael E. Shy, Asian Oceanic Inheri Consortium, Katie Stephens, Stephan Zuchner
4:40 p.m. ET S12.005
Description of Clinical Symptoms of a Large International Cohort of Patients with Valosincontaining-protein Related Disease—Marta Caballero-Avila, Chiseko Ikenaga, Chiara MariniBettolo, Michela Guglieri, Volker Straub, Rocio Nur Villar Quiles, Sarah Souvannanorath, Pascal Lafort, Tanya Stojkovic, Conrad Weihl, Jordi Diaz-Manera
4:48 p.m. ET
Questions and Answers
Monday, April 19, 2021
S13 Advances in General Neurology CME 1
2:00 p.m. ET S13.001
HELIOS-A: 9-month Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy—David D. Adams, Ivajlo Tournev, Mark Taylor, Teresa Coelho, Violaine PlanteBordeneuve, John L. Berk, Alejandra Gonzalez-Duarte, Julian D. Gillmore, Soon Chai Low, Yoshiki Sekijima, Laura Piera Obici, Rick Blakesley, Seth Arum, Rebecca Shilling, John Vest, Michael J. Polydefkis
2:08 p.m. ET S13.002
A Computational Model of the Mutations of Cu-Zn Superoxide Dismutase 1 and Mechanisms for Protein Misfolding in Amyotrophic Lateral Sclerosis with Theoretical Nuclear Physics Methods—Joao Marcos Brandet
2:16 p.m. ET
Questions and Answers
2:24 p.m. ET S13.003
Characterization of the Associations Between Pre-diabetes and Diabetes with Occurrence of Stroke by its Types, Subtypes, and Outcomes among West Africans—Mayowa Owolabi, Fred Sarfo, Kolawole W. Wahab, Albert K. Akpalu, Reginald Obiako, Edward Komolafe, Lukman Femi Owolabi, Godwin Osawaru Osaigbovo, Onoja Matthew Akpa, Joshua O. Akinyemi, Rufus O. Akinyemi, Bruce I. Ovbiagele
2:32 p.m. ET S13.004
Cortical Oligodendrocyte Gene Networks Regulated by miR-142-3p are Associated with Tauopathy in Mice and Humans—Brent L. Fogel, Kathie Ngo, Cidi Chen, Carmela Abraham, Mohsen Ghanbari, Mohammad Ikram, Steven Kushner, Riki Kawaguchi, Giovanni Coppola, Kerstin Goth, Saverio Bellusci, Israel Hernandez, Kenneth S. Kosik, Jason D. Hinman
2:40 p.m. ET S13.005
Plasma Phosphorylated Neurofilament Heavy Chain (pNF-H) Level is Associated with Future Motor Function in Nusinersen-treated Individuals with Later-onset Spinal Muscular Atrophy (SMA)—Michelle A. Farrar, Francesco Muntoni, Charlotte J. Sumner, Thomas O. Crawford, Richard S. Finkel, Eugenio Mercuri, Xiaotong Jiang, Jihee Sohn, Marco Petrillo, Steve Garafalo, Wildon Farwell
2:48 p.m. ET
Questions and Answers
S14 Behavioral and Cognitive
Neurology
CME 1
2:00 p.m. ET S14.001
Cortical Microstructure in Primary Progressive Aphasia: A Multicenter Study—Ignacio IllanGala, Victor Montal, Sergi Borrego Ecija, Neus Falgas Martinez, Maria Luisa Mandelli, Ariane E. Welch, Jordi Pegueroles, Daniel Alcolea Rodriguez, Mara Belan Sanchez Saudinos, Jordi Clarimon, Nuria Bargallo, Sofia Gonzalez-Ortiz, Albert Llado, Rafael G. Blesa, Howard J. Rosen, Bruce L. Miller, Maria Gorno Tempini, Raquel Sanchez-Valle, Alberto Lleo, Juan Fortea
2:08 p.m. ET S14.002
Shorter Survival in Logopenic Progressive Crossed Aphasia in Dextrals—Marina Buciuc, Joseph Duffy, Mary M. Machulda, Jonathan GraffRadford, Nha Trang Thu Pham, Peter Martin, Matthew Senjem, Clifford R. Jack, Dennis W. Dickson, Val John Lowe, Jennifer Louise Whitwell, Keith A. Josephs
2:16 p.m. ET
Questions and Answers
2:24 p.m. ET S14.003
A Highly Efficient Method for Single-Cell Electroporation in Mouse Organotypic Hippocampal Slice Culture—Amy Cheung, Kensuke Futai
2:32 p.m. ET S14.004
Lateralization of Motor Damage Influences the Features of Cognitive Impairment in ALS— Adriano Chio, Laura Peotta, Barbara Iazzolino, Rosario Vasta, Francesca Palumbo, Maria Claudia Torrieri, Luca Solero, Cristina Moglia, Antonio Canosa, Marco Pagani, Umberto Manera
2:40 p.m. ET S14.005
A Different Cognitive and Behavioral Profile in ALS Patients With or Without C9 or F72 Expansion—Cristina Moglia, Barbara Iazzolino, Laura Peotta, Jean Pierre Zucchetti, Antonio Canosa, Francesca Palumbo, Umberto Manera, Maura Brunetti, Andrea Calvo, Adriano Chio
2:48 p.m. ET
Questions and Answers
S15 Headache 2
CME 1
2:00 p.m. ET S15.001
Impact of Abuse on Migraine Symptoms and Comorbidity: Results from the American Registry for Migraine Research (ARMR)— Meesha Trivedi, Gina Dumkrieger, Catherine Daniela Chong, David W. Dodick, Todd J. Schwedt
2:08 p.m. ET S15.002
Understanding the Impact of Sex and Race on the Migraine Patient’s Journey in the United States: Analyses From an Annual CrossSectional Patient Chart Audit—Robert Cowan, Meg Stabb, Nicholas Robinson, Virginia Schobel
2:16 p.m. ET
Questions and Answers
2:24 p.m. ET S15.003
Mindfulness Meditation vs. Headache Education for Migraine: A Randomized Clinical Trial— Rebecca E. Wells, Nathaniel O'Connell, Charles Pierce, Paige Estave, Donald B. Penzien, Elizabeth Loder, Fadel Zeidan, Timothy Houle
2:32 p.m. ET S15.004
Assessing Barriers to Care in Episodic and Chronic Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study—Dawn C. Buse, Cynthia Emilie Armand, Larry Charleston, Michael L. Reed, Kristina Fanning, Aubrey Manack Adams, Richard B. Lipton
2:40 p.m. ET S15.005
Calcitonin Gene-Related Peptide Inhibitor Use for Migraine Associated with Exacerbation of Raynaud Phenomenon—Ilana Breen, Caitlin Brumfiel, Meera Simmi Patel, Juliana VanderPluym, Aaron Griffing, Mark Pittelkow, Aaron Mangold
2:48 p.m. ET
Questions and Answers
S16 Neuro-oncology
CME 1
4:00 p.m. ET S16.001
Prognostic Importance of the Extent of Resection in IDH-wild Type Grade II Astrocytomas According to EGFR Amplification and pTERT Mutation—Francesco Bruno, Valeria Interno, Alessia Pellerino, Antonio Silvani, Tamara Ius, Lorenzo Bello, Giuseppe Lombardi, Andrea Pace, Giuseppe Minniti, Riccardo Soffietti, Roberta Ruda
4:08 p.m. ET S16.002
Clinical and Survival Characteristics of Gliosarcoma Patients—Ahmad Amer, SWAPNIL KHOSE, Hamza Alhasan, Halyna Pokhylevych, Gregory Fuller, Noah Chasen, John F. De Groot, Jason Johnson
4:16 p.m. ET
Questions and Answers
4:24 p.m. ET S16.003
Adult Pilocytic Astrocytoma in the Molecular Era: Surveying the Prevalence of MAPK Pathway Dysfunction and Overlap with Aggressive Features—Timothy Gregory, Lyndon Chumbley, Brett J. Theeler
4:32 p.m. ET S16.004
Long-term Follow-up of Schwannoma Growth Behavior in Adult Neurofibromatosis Type 2 and Schwannomatosis Patients Using Whole-body MRI—Ina Ly, Raquel D. Thalheimer, Wenli Cai, Miriam Bredella, Alona Muzikansky, Vanessa Merker, Hamilton Herr, Jennifer Da, Gordon Harris, Scott R. Plotkin, Justin T. Jordan
4:40 p.m. ET S16.005
Clinical and Molecular Features of a Prospectively-Sequenced Cohort of Glioblastoma Patients with Inherited Disorders in Mismatch Repair—Kevin Elmore, Zsofia Stadler, Anna Piotrowski, Lauren Rhea Schaff, Igor T. Gavrilovic, Jacqueline Stone, Ira Dunkel, Viviane Tabar, Ingo K. Mellinghoff, Tejus Bale, Andrew L. Lin
4:48 p.m. ET
Questions and Answers
Monday, April 19, 2021
S17 History of Neurology
CME 1 S18 Health Care Disparities
CME 1
4:00 p.m. ET S17.001
Historical Perspectives of Thrombolysis in Acute Ischemic Stroke Before the Alteplase Era—Jorge Guy Ortiz-Garcia, Ronald Alvarado Dyer, Faddi Ghassan M. Saleh Velez
4:08 p.m. ET S17.002
Powdered Human Skulls in New Spain: Epilepsy Care before Pedro de Horta, the First American Epileptologist—Guillermo Ruben Delgado-Garcia, Carolina Rodriguez-Navarez, Bruno Estanol Vidal
4:16 p.m. ET
Questions and Answers
4:24 p.m. ET S17.003
The Color of Neurology Workforce—Aminah Abdul Razzack
4:32 p.m. ET S17.004
Disentangling the Gordian Knot: The Birth, Father, and Future of Balloon Embolization— Victor Ekuta
4:40 p.m. ET S17.005
Dr. Betty G. Clements: Breaking Gender Barriers in the Air Force and Neurology—Elizabeth A. Coon, Christopher J. Boes
4:48 p.m. ET
Questions and Answers
4:00 p.m. ET S18.001
Sociodemographic and Clinical Characteristics of Patients With Multiple Sclerosis by Race and Ethnicity (NARCRMS Registry)—Victor M. Rivera, Pavle Repovic, Ayo Adeyemi, Arman Altincatal, Coraly Perez Bajandas, Toni Saldana-King, Wanda CastroBorrero
4:08 p.m. ET S18.002
Race/ethnicity and Insurance Status Impact Acute Ischemic Stroke Treatment within Three Large U.S. States—Alison Herman, Lindsey Ray Kuohn, Guido Jose Falcone, Richa Sharma, David Y. Hwang, Kevin N. Sheth, Jennifer A. Kim
4:16 p.m. ET
Questions and Answers
4:24 p.m. ET S18.003
Racial Disparities with Last Known Normal Time in Patients with Acute Ischemic Stroke— Mangala Gopal, Vivien H. Lee
4:32 p.m. ET S18.004
An Assessment of Gender and Racial/Ethnic Diversity amongst Neurology Residents and Physicians—Fabiola Valenzuela, Minerva Romero Arenas
4:40 p.m. ET S18.005
Creation of a Longitudinal, Clinical Undergraduate Pipeline Program to Engage Underrepresented Individuals in Neurology— Robert Ian Thompson-Stone
4:48 p.m. ET
Questions and Answers
Tuesday, April 20, 2021
S19 Aging and Dementia
CME 1
2:00 p.m. ET S19.001
Preliminary Analysis Of BAN2401 Effects On Brain Amyloid And ARIA-E Findings Over 12 Months Of Treatment In The OpenLabel Extension Of The Phase2b Study BAN2401-G000-201 In Subjects With Early Alzheimer’s Disease—Chad J Swanson, Shobha Dhadda, Mark Hodgkinson, David Li, Michio Kanekiyo, June Kaplow, Martin Rabe, Helena Heanue-travers, Robert Gordon, Robert YK Lai, Lynn D. Kramer
2:08 p.m. ET S19.002
A Comparative Study of Plasma t-tau and Neurofilament Light Chain in Frontotemporal Lobar Degeneration and Alzheimer’s Disease— Ignacio Illan-Gala, Alberto Lleo, Adam Staffaroni, Henrik Zetterberg, Agnieszka Kieloch, Lea Grinberg, Salvatore Spina, Joel Kramer, Eliana Marisa Ramos, Giovanni Coppola, Renaud La Joie, Gil Dan Rabinovici, David C. Perry, Maria Gorno Tempini, William Seeley, Bruce L. Miller, Howard J. Rosen, Adam L. Boxer, Julio C. Rojas -Martinez
2:16 p.m. ET
Questions and Answers
2:24 p.m. ET S19.003
History of Psychiatric Disease Inversely Correlates with Age of Onset in Alzheimer’s Disease—Emily Eijansantos, Isabel Allen, Jessica Deleon, Stephanie Grasso, Nicole Rogers, Rian Bogley, David C. Perry, Virginia Sturm, Howard J. Rosen, Lea Grinberg, William Seeley, Bruce L. Miller, Gil Dan Rabinovici, Maria Gorno Tempini, Zachary Miller
2:32 p.m. ET S19.004
Breast Cancer Therapies Reduce Risk of Alzheimer’s Disease and Dementia: Clinic to Bench Translation—Greg Lawrence Branigan, Greg Lawrence Branigan, Kathleen Rodgers, Roberta Diaz Brinton
2:40 p.m. ET S19.005
Motor Function in Patients with Neuropsychiatric Manifestations of Neurodegenerative Disease Treated with Pimavanserin—Daniel Weintraub, Erin P. Foff, Clive G. Ballard, Bradley W. McEvoy, Bruce Coate, George Demos, Ana Lilliam Berrio, Brandon Abbs, James Maurice Youakim, Srdjan Stankovic
2:48 p.m. ET
Questions and Answers
S20 Motor Neuron Disease/
Amyotrophic Lateral Sclerosis
CME 1
2:00 p.m. ET S20.001
Design of a Phase 3, Randomized, Placebocontrolled Trial of Tofersen Initiated in Clinically Pre-symptomatic SOD1 Mutation Carriers with a Longitudinal Natural History Run-in—Michael G. Benatar, Joanne Wuu, Peter Munch Andersen, Jinsy Andrews, Bob Bucelli, Markus Otto, Toby A. Ferguson, Weiping Chen, Laura Fanning, Danielle Graham, Peng Sun, Yingying Liu, Janice Chun Yee Wong, Stephanie Fradette
2:08 p.m. ET S20.002
Clinical Utility of Whole-Genome Sequencing in an ALS Cohort—Adriano Chio, Andrea Calvo, Cristina Moglia, Maura Brunetti, Ruth Chia, Jinhui Ding, J. Raphael Gibbs, Clifton Dalgard, Sonja Waltraud Scholz, Bryan Traynor, Letizia Mazzini, Fabiola De Marchi, Lucia Corrado, Sandra D'Alfonso, Maurizio Grassano
2:16 p.m. ET
Questions and Answers
2:24 p.m. ET S20.003
Determinants of Clinical Response to Levosimendan in the REFALS pPhase 3 Study in People with ALS—Merit E. Cudkowicz, Angela L. Genge, Nicholas J. Maragakis, Susanne Petri, Leonard H. Van den Berg, Valtteri Aho, Chris Garratt, Toni Sarapohja, Ammar Al-Chalabi
2:32 p.m. ET S20.004
Metabolic Brain Changes Across Different Levels Of Cognitive Impairment In ALS: A 18F-FDG-PET Study—Antonio Canosa, Cristina Moglia, Umberto Manera, Rosario Vasta, Maria Claudia Torrieri, Vincenzo Arena, Fabrizio D'Ovidio, Francesca Palumbo, Jean Pierre Zucchetti, Barbara Iazzolino, Laura Peotta, Andrea Calvo, Marco Pagani, Adriano Chio
2:40 p.m. ET S20.005
WVE-004, An Investigational Stereopure Antisense Oligonucleotide for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)—Yuanjing Liu, Amy Andreucci, Elena Dale, Yuan Yin, Hailin Yang, Fangjun Liu, Saurabh Patil, Susovan Mohapatra, Erin Purcell-Estabrook, Kristin Taborn, Elena Dale, Chandra Vargeese
2:48 p.m. ET
Questions and Answers
Tuesday, April 20, 2021
S21 Neuroepidemiology
CME 1
2:00 p.m. ET S21.001
Effect Of Linoleic Acid On Ischemic Stroke: A Mendelian Randomization Study—David Wu, Huijun Huang, Yu Qian, Yingying Mao
2:08 p.m. ET S21.002
Midlife Cardiac Structure And Function Are Associated With Lower Midlife Cognition: The CARDIA Study—Laure Rouch, Laure Rouch, Feng Xia, Stephen Sidney, Joao Lima, Kristine Yaffe
2:16 p.m. ET
Questions and Answers
2:24 p.m. ET S21.003
Anomalously Warm Weather and Acute Care Visits in Patients with Multiple Sclerosis: A Retrospective Study of Privately Insured Individuals in the U.S.—Holly Elser, Robbie Parks, Nuriel Moghavem, Mathew Kiang, Nina Bozinov, Victor W. Henderson, David Rehkopf, Joan Casey
2:32 p.m. ET S21.004
COVID-19 Outcomes in Hospitalized Patients with Pre-existing Neurodegenerative Diseases in Chicagoland Area—Roshni A. Patel, Glenn Thurston Stebbins, Brandon Barton
2:40 p.m. ET S21.005
Persistent Chemosensory Dysfunction Associated with COVID-19 Infection in a Cohort of over 800 Health Care Workers—Nicholas Bussiere, Jie Mei, Mathieu Blais, Francois Gros-Louis, Gaston De Serres, Nicolas Dupre, Johannes Frasnelli
2:48 p.m. ET
Questions and Answers
S22 Cerebrovascular Disease and
Interventional Neurology:
Biomarkers, Mechanisms of
Axonal Injury, Stroke, and
Infection
CME 1
2:00 p.m. ET S22.001
Retinal Microvascular Changes and Vessel Diameters are Moderately Associated with Positive Magnetic Resonance Diffusion Weighted Imaging (MR-DWI) among Patients Presenting to the Emergency Department (ED) with Suspected TIA: The FOTO-TIA Study—Beau Benjamin Bruce, Samuel Bidot, Fadi B. Nahab, Jeffery Siegelman, Kaitlin Sandor, Mung Yan Lin, Benjamin Meyer, Michael Ross, David W. Wright, Valerie Biousse, Nancy J. Newman
2:08 p.m. ET S22.002
What are the Molecular Mechanisms of Axonal Degeneration in Stroke?—Jack Tzu-Chieh Wang
2:16 p.m. ET
Questions and Answers
2:24 p.m. ET S22.003
Significant Increase in Mortality and Risk of Acute Ischemic Stroke in Infective Endocarditis Patients with Subarachnoid Hemorrhage—Tolga Sursal, Zafar Karimov, Andrew Nazarenko, Linda Ye, Fawaz Al-Mufti
2:32 p.m. ET S22.004
Global Frequency of Stroke in Tuberculous Meningitis: A Systematic Review and Metaanalysis—Marie Charmaine Sy, Marie Charmaine Sy, Jose Leonard R Pascual
2:40 p.m. ET S22.005
Dental Caries Associated with Incident Ischemic Stroke: Atherosclerosis Risk In Communities Study—Souvik Sen, James Curtis, David Hicklin, Cindy Nichols, Wayne Rosamond, Rebecca F. Gottesman, Kevin Moss, Kimon Divaris, James Beck, Steven Offenbacher
2:48 p.m. ET
Questions and Answers
S23 Research Methodology and
Education
CME 1
4:00 p.m. ET S23.001
Feasibility and Short-Term Outcomes of the MGH Youth Neurology Education and Research Program—Madison Ellin, Alazar Ayele, Johanna Jobin, Jennifer Peak Rubin, Nicte I. Mejia
4:08 p.m. ET S23.002
Extending the Duration of the Neurology Clerkship – Does it Matter?—Jorge Eduardo Patino Murillas, Zafer Keser, Yvo Andres RodriguezLinares, Rachel Cantu Beck, Luke Kupcha, Louise D. McCullough, Stefano Sandrone, Erin Furr-Stimming
4:16 p.m. ET
Questions and Answers
4:24 p.m. ET S23.003
Adult Neurology Rotations for Child Neurology Residents: Exploring the Resident Perspective—Stella Deng, Cullen Spencer Marshall, Donald Gilbert, Hannah Jackson, David Wolf, Robert Ian Thompson-Stone
4:32 p.m. ET S23.004
A Roadmap to Patient Engagement: FSHD and the ReSolve Clinical Trial—Samantha Jo LoRusso, Katy Eichinger, Kiley Higgs, Leann Lewis, Michaela Walker, Alrabi Tawil, Jeffrey Statland, Kim Kimminau
4:40 p.m. ET S23.005
Industry-related Financial Conflicts of Interest Amongst Authors of Neurology Clinical Practice Guidelines—Ian Fladie, Bryan Wright, Nathaniel Michael Robbins, Matt Vassar
4:48 p.m. ET
Questions and Answers
S24 Pain and Palliative Care:
Targeted Therapy in Chronic
Pain Disorders
CME 1
4:00 p.m. ET S24.001
Peripheral Neurological Safety of Subcutaneous Tanezumab versus Placebo or NSAIDs in Patients with Osteoarthritis—Mark T. Brown, Paola Sandroni, Kenneth C. Gorson, Phillip A. Low, David Hunter, Glenn C. Pixton, Robert Fountaine, Lars Viktrup, Elizabeth Johnston, Christine R. West, Kenneth M. Verburg
4:08 p.m. ET S24.002
Role of HINT1 in Neuropathic Pain: Insights Provided by Studies on the Spared Nerve Injury Model and HINT1 Inhibition—Rishi Sharma, Cristina Peterson, Kelley Kitto, Carolyn Fairbanks, Carston Wagner, George Wilcox
4:16 p.m. ET
Questions and Answers
4:24 p.m. ET S24.003
Reduction in Pain During and Between Attacks in Patients with Acute Hepatic Porphyria Treated with Givosiran: A Post-Hoc Analysis of the Phase 3 ENVISION Study—Susana Monroy, Raili Kauppinen, Hung-Chou Kuo, Jeeyoung Oh, Ole Hother-Nielson, Mary-Jean Fanelli, Zhaowei Hua, Qiuling He, John Ko, Amy Simon, David Rees
4:32 p.m. ET S24.004
Conus Medullaris Syndrome and Cauda Equina Syndrome after Lumbar Epidural Steroid Injection: A Systematic Review of Literature— Aimen Vanood, Bhavneet Singh, Katherine Elizabeth Wheeler, Gustavo A. Patino
4:40 p.m. ET S24.005
Exploratory Study of Acoustic Neuromodulation Improves Pain, Autonomic Function, and Symptoms of Insomnia, Stress, and Anxiety in Individuals with Chronic Pain—Catherine Tegeler, Lindsay Joanna Howard, Kenzie Brown, Dawn Kellar, Faiza Asif-Fraz, Lee Gerdes, Charles H. Tegeler, Hossam Shaltout
4:48 p.m. ET
Questions and Answers
Tuesday, April 20, 2021 Wednesday, April 21, 2021
S25 MS and CNS Inflammatory
Disease: Emerging Therapeutics and Biomarkers
CME 1
4:00 p.m. ET S25.001
Associations of Serum Neurofilament Light Chain with Clinico-Radiological Characteristics in the MSPATHS Network: A Cross-Sectional Evaluation—Elias S. Sotirchos, Kathryn Fitzgerald, Matthew Smith, James Rhys Williams, Carl DeMoor, Suzanne Szak, Carol Singh, Elizabeth Fisher, Robert A. Bermel, Carrie Michelle Hersh, Megan Hyland, Lauren B. Krupp, Xavier Montalban, Robert T. Naismith, Jacqueline Ann Nicholas, Manuel Comabella Lopez, Tjalf Ziemssen, Ellen M. Mowry, Peter A. Calabresi
4:08 p.m. ET S25.002
Brain-homing B cells in Multiple Sclerosis: Association with Bruton’s Tyrosine Kkinase and Targeting by Evobrutinib—Liza Rijvers, Marie-Jose Melief, Jamie Van Langelaar, Rudi Hendriks, Ursula Boschert, Roland Grenningloh, Joost JFM Smolders, Marvin Van Luijn
4:16 p.m. ET
Questions and Answers
4:24 p.m. ET S25.003
Establishing a Role for the Bruton’s Tyrosine Kinase Inhibitor Tolebrutinib in Modulating Neuroinflammation and Disease Progression in MS—Ross C. Gruber, Michael R Dufault, Nathalie Chretien, Jonathan Proto, Mindy Zhang, Evis Havari, Timothy J. Turner, Anthony Chomyk, Emilie Christie, Bruce D. Trapp, Dimitry Ofengeim
4:32 p.m. ET S25.004
Efficacy and Safety of Tolebrutinib in Patients With Highly Active Relapsing MS: Subgroup Analysis of the Phase 2b Study—Sana Syed, Nicole L. Yonkers, Christopher C. LaGanke, William David Honeycutt, Anthony Traboulsee, Daniel R. Wynn, Sibyl E. Wray, Petr Prochazka, Deborah Dukovic, Timothy J. Turner
4:40 p.m. ET S25.005
The Safety of Fenebrutinib in a Large Population of Patients With Diverse Autoimmune Indications Supports Investigation in Multiple Sclerosis (MS)—Jiwon Oh, Stanley L. Cohen, David Isenberg, Marcus Maurer, Joshua Galanter, Tom Chu, Anastasia Teterina, Alexandra L. Goodyear, Corey Mandel, Chin Lee, Katie Tuckwell, Jeremy Lim, Konstantina Vanevski, Gavin Giovannoni
4:48 p.m. ET
Questions and Answers
S26 Neurocritical Care
CME 1
2:00 p.m. ET S26.001
Higher Systolic Blood Pressure Variability After Endovascular Thrombectomy Is Associated with Poor Functional Outcome—Ayush Prasad, Jessica Kobsa, Sreeja Kodali, Cindy Khanh Phuong Nguyen, Darko Ernesto Quispe Orozco, Mudassir Farooqui, Cynthia Zevallos, Santiago Ortega Gutierrez, Mohammad Anadani, Eyad Almallouhi, Joontae Kim, Ilko Maier, Nolwenn Riou-Comte, Stacey Wolfe, Patrick Brown, Kyle Fargen, Eva Mistry, Hiba Fakhri, Akshitkumar Mistry, Ka-Ho Wong, Adam De Havenon, Fabio Nascimento, Kevin N. Sheth, Nils Petersen
2:08 p.m. ET S26.002
Post-Intensive Care Syndrome Impacts Quality of Life in Critically Ill Stroke Patients—Kelsey Cacic, Natalie Kreitzer, Neha Dangayach, E. Wesley Ely, Brandon P. Foreman
2:16 p.m. ET
Questions and Answers
2:24 p.m. ET S26.003
Shared Decision-making in Goals-of-care Meetings for Critically Ill Neurologic Patients: A Multi-center Study—Abhinav Vibhas Prasad, Connie Ge, Kelsey Goostrey, Beshoy Armanios, Praewpannanrai Buddadhumaruk Sun, Catherine L Hough, Jay Steingrub, Douglas White, Susanne Muehlschlegel
2:32 p.m. ET S26.004
A Machine Learning Algorithm for Predicting Outcome after Subarachnoid Hemorrhage—Hsin Yi Chen, Wei-Long Zheng, Sahar Fatima Zafar, Jonathan Elmer, Manohar Ghanta, Valdery Moura, Aman Patel, Eric Rosenthal, Emily Jean Gilmore, M. Brandon Westover, Jennifer A. Kim
2:40 p.m. ET S26.005
von Willebrand Factor (vWF) as a Biomarker of Traumatic Brain Injury—Rachel Elizabeth Thomas, Joshua Gatson, Erika Silverman, Leroy Wesley, My Duyen Le, Justin Alexander Morrison, Cian Dabrowski, Brigid Anne Magdamo, Jeff Debad, Christopher Campbell, Danielle Sandsmark, Ramon R. Diaz-Arrastia
2:48 p.m. ET
Questions and Answers
S27 Movement Disorders: Basic
Science
CME 1
2:00 p.m. ET S27.001
Antigen-presenting Cells from PD Patients Exhibit an Autoinflammatory Cytokine Profile—Camille Michaud, Camberly Hernandez, Annie Laplante, Sebastien Audet, Renaud Balthazard, Martine Tetreault, Diana Matheoud
2:08 p.m. ET S27.002
The Role of Mitochondrial Antigen Presentation in the Establishment of Parkinson's Diseaselike Symptoms—Moustafa Nouh Badr, Renaud Balthazard, Annie Laplante, Diana Matheoud
2:16 p.m. ET
Questions and Answers
2:24 p.m. ET S27.003
SV2C is Required for Nicotine-mediated Rescue of Alpha-synuclein Neurotoxicity—Sabrina Clemens, Abby Lauren Olsen
2:32 p.m. ET S27.004
ATH434 Preserves Dopaminergic Neurons, Reduces a-synuclein Oligomerization, and Improves Motor Function in a Transgenic Murine Multiple System Atrophy Model—Antonio HeraGarvin, Violetta Refolo, Margaret Bradbury, David A. Stamler, Nadia Stefanova
2:40 p.m. ET S27.005
Essential Tremor versus “ET-plus”: A Postmortem Study—Elan D. Louis, John Gionco, Whitney Hartstone, Regina Martuscello, Sheng-Han Kuo, Phyllis Faust
2:48 p.m. ET
Questions and Answers
S28 Clinical Decision Making in MS CME 1
2:00 p.m. ET S28.001
Identifying Distinct Cognitive Phenotypes in Multiple Sclerosis—Ermelinda De Meo, Emilio Portaccio, Antonio Giorgio, Luis Ruano, Benedetta Goretti, Claudia Niccolai, Francesco Patti, Clara Chisari, Paolo Gallo, Paola Grossi, Angelo Ghezzi, Marco Roscio, Flavia Mattioli, Chiara Stampatori, Marta Simone, Rosa G. Viterbo, Raffaello Bonacchi, Maria Assunta Rocca, Nicola De Stefano, Massimo Filippi, Maria Pia Amato
2:08 p.m. ET S28.002
Different Disease Modifying Therapies Can Increase or Decrease Covid-19 Severity in Multiple Sclerosis—Maria Pia Sormani, Nicola De Rossi, Irene Schiavetti, Luca Carmisciano, Cinzia Cordioli, Lucia Moiola, Marta Radaelli, Paolo Immovilli, Marco Alfonso Narduc Capobianco, Maria Trojano, Paola Zaratin, Gioacchino Tedeschi, Giancarlo Comi, Mario Battaglia, Francesco Patti, Marco Salvetti
2:16 p.m. ET
Questions and Answers
2:24 p.m. ET S28.003
Determinants of Recovery from the Coronavirus Disease 2019 in People with Multiple Sclerosis: The UK MS Register COVID-19 Prospective Cohort Study—Afagh Garjani, Richard St. John Nicholas, Rod Middleton, Katherine Tuite-Dalton, Rachael Hunter, Roshan Das Nair, Nikolaos Evangelou
2:32 p.m. ET S28.004
Delay from Treatment Start to Full Effect of Immunotherapies for Multiple Sclerosis—Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, J William L. Brown, Dana Horakova, Eva Havrdova, Maria Trojano, Francesco Patti, Guillermo Izquierdo Ayuso, Sara Eichau Madueño, Marco Onofrj, Alessandra Lugaresi, Alexandre Prat, J M. Girard, Pierre Grammond, Patrizia Sola, Diana Ferraro, Serkan Ozakbas, Roberto Bergamaschi, Maria Jose Sa, Elisabetta Cartechini, Cavit Boz, Franco Granella, Raymond Hupperts, Murat Terzi, Jeannette LechnerScott, Daniele Litterio A. Spitaleri, Vincent Van Pesch, Aysun Soysal, Javier Olaskoaga, Julie Prevost, Eduardo Aguera Morales, Mark Slee, Tunde Csepany, Recai Turkoglu, Youssef Sidhom, Riadh Gouider, Bart Van Wijmeersch, Pamela Ann McCombe, Richard A L Macdonell, Alasdair Coles, Charles Malpas, Helmut Butzkueven, Sandra Vukusic, Tomas Kalincik
2:40 p.m. ET S28.005
Early Clinical and MRI Predictors of Longterm Disability in Pediatric Multiple Sclerosis Patients—Ermelinda De Meo, Raffaello Bonacchi, Lucia Moiola, Francesca Sangalli, Bruno Colombo, Giancarlo Comi, Vittorio Martinelli, Maria Assunta Rocca, Maria Pia Amato, Massimo Filippi
2:48 p.m. ET
Questions and Answers
Wednesday, April 21, 2021
S29 Autoimmune Neurology: Clinical
Trials, Treatment, and Diagnosis of CNS and PNS Autoimmune
Neurologic Disorders
CME 1
4:00 p.m. ET S29.001
Topline Results of a Phase 2 Study of Subcutaneous IMVT-1401 in Patients with Generalized Myasthenia Gravis—Michael G. Benatar, Ari Breiner, Vera Bril, Richard J. Nowak, Imogene Dunn, Alan R. Jacobs
4:08 p.m. ET S29.002
Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, PlaceboControlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis—Jeff Guptill, Carlo Antozzi, Vera Bril, Josep Gamez, Sven G. Meuth, Jose Luis Munoz Blanco, Richard J. Nowak, Dianna Quan, Teresa Sevilla, Andrzej Szczudlik, Brooke W Hegarty, Marie-Helene Jouvin, Jim Jin, Santiago Arroyo
4:16 p.m. ET
Questions and Answers
4:24 p.m. ET S29.003
Pharmacodynamic Modeling and Exposureresponse Assessment of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders—Li Yan, Bing Wang, Dewei She, Benjamin Mitchell, Ryan Criste, Daniel M. Cimbora, Eliezer Katz, William Rees
4:32 p.m. ET S29.004
Long-term Efficacy and Safety of Eculizumab Monotherapy in AQP4+ Neuromyelitis Optica Spectrum Disorder—Sean J. Pittock, Kazuo Fujihara, Jacqueline Palace, Achim Berthele, Ho Jin Kim, Celia Oreja Guevara, Ichiro Nakashima, Michael Levy, Shulian Shang, Marcus Yountz, Larisa Miller, Roisin Armstrong, Dean M. Wingerchuk
4:40 p.m. ET S29.005
The Positive Predictive Value of MOG Autoantibody Live Cell-Based Assay in a Tertiary Referral Center—Elia Sechi, Marina Buciuc, Sean J. Pittock, John Chen, James Fryer, Adrian Budhram, Brian G. Weinshenker, Christine Beattie, Andrew McKeon, John R. Mills, Eoin P. Flanagan
4:48 p.m. ET
Questions and Answers
CME 1
4:00 p.m. ET S30.001
Safety and Efficacy of the Telestroke Dripand-Stay Model: A Systematic Review and Meta-analysis—Hena Waseem, Yasir Salih, Charles Burney, Mark Abel, Natalie Riblet, Nathaniel Michael Robbins
4:08 p.m. ET S30.002
Race and Ethnicity Influence Perihematomal Edema Volume in Supratentorial Intracerebral Hemorrhage—Julian Acosta, Yasheng Chen, Cameron Both, Audrey Leasure, Fernando Testai, Daniel Woo, Jin Moo Lee, Kevin N. Sheth, Rajat Dhar, Guido Jose Falcone
4:16 p.m. ET
Questions and Answers
4:24 p.m. ET S30.003
Improved Identification of FAST Stroke Signs in the Population After Multiple Public Awareness Campaigns in Quebec, Canada—Vincent Brissette, Bastien Rioux, Francine Forget Marin, Patrice Lindsay, Alexandre Y. Poppe
4:32 p.m. ET S30.004
Stroke Disparities Across Racial and other Minorities: Results from the “All of Us” Research Program—Julian Acosta, Audrey Leasure, Cameron Both, Natalia Szejko, Victor Torres-Lopez, Kevin N. Sheth, Guido Jose Falcone
4:40 p.m. ET S30.005
Nationwide Racial Disparities in Smoking Cessation after Stroke in the United States— Neal S. Parikh, Melvin Parasram, Yongkang Zhang, Saad Abdul Sami Mir, Halina White, Babak Navi, Hooman Kamel
4:48 p.m. ET
Questions and Answers
S31 Infectious Disease: Stroke and
Infectious Diseases
CME 1
4:00 p.m. ET S31.001
Injection Drug Use and Right-sided Endocarditis - Are We Missing the Strokes?—Karan Hingorani, Erin Barnes, Thiago Santos Carneiro, Pria Anand, Charlene Jennifer Ong, David Young Chung, Ali Daneshmand, Kushak Suchdev, Courtney Takahashi, David M. Greer, Julie Grimes Shulman, Hugo Javier Aparicio, Thanh Ngoc Nguyen, Jose Rafael Romero, Mohamad Abdalkader, Simeon Kimmel, Zoe Weinstein, Maura Fagan, Nikola Dobrilovic, Eric Awtry, Anna Marisa Cervantes-Arslanian
4:08 p.m. ET S31.002
Acute Hospital Outcomes COVID-19 Associated Neurological Dysfunction—Nicole Paul, Aleksandra Safonova, Valeria Altamirano, Michal Hammond, Ali Scott, Aditya Sharma, Abigail Skeel, Charith Ratnayake, Carlos Villamizar Rosales, Sherry Chou
4:16 p.m. ET
Questions and Answers
4:24 p.m. ET S31.003
Neuropathological Features of COVID-19—Erica Normandin, Shamik Bhattacharyya, Shibani Sharon Mukerji, Kiana Keller, Ahya Sajawal Ali, Gordon Adams, Jason Hornick, Robert Padera, Pardis Sabeti, Isaac H Solomon
4:32 p.m. ET S31.004
Cerebral Venous Thrombosis In COVID-19 : A New York City Metropolitan Cohort Study— Fawaz Al-Mufti, Hussein Alshammari, Ramandeep Sahni, Rolla Nouman, Philip Overby, Jared Cooper, Haris Kamal, Katarina B. Dakay, Stephan A. Mayer, Chirag Gandhi
4:40 p.m. ET S31.005
Neutrophil-Lymphocyte Ratio Associated with Poor Clinical Outcome after Mechanical Thrombectomy Following Large Vessel Occlusion Stroke in Patients with COVID-19— Fawaz Al-Mufti, Tolga Sursal, Hussein Alshammari, Chirag Gandhi, Stephan A. Mayer
4:48 p.m. ET
Questions and Answers
S32 Therapeutics of Genetic Neuromuscular Diseases
CME 1
4:00 p.m. ET S32.001
Global Open-label Extension: 24-month Data in Patients with hATTR Amyloidosis—David D. Adams, Alejandra Gonzalez-Duarte, Elizabeth Ann Mauricio, Thomas H. Brannagan, Teresa Coelho, Jonas Wixner, Erhan Berber, Marianne T. Sweetser, Matthew White, Jing Jing Wang, Michael J. Polydefkis
4:08 p.m. ET S32.002
Impact of Patisiran on Activities of Daily Living and Functional Status in hATTR Amyloidosis— Amanda C. Peltier, Alejandra Gonzalez-Duarte, John L. Berk, Ivailo Tournev, Ole Suhr, Senda Ajroud-Driss, Madeline Merkel, Hollis Lin, Cecilia Hale, David D. Adams
4:16 p.m. ET
Questions and Answers
4:24 p.m. ET S32.003
Safety, ß-sarcoglycan Expression and Functional Outcomes from Systemic Gene Transfer of rAAVrh74.MHCK7.SGCB in Patients with Limb-Girdle Muscular Dystrophy Type 2E (LGMD2E)—Louise R. Rodino-Klapac, Eric Pozsgai, Sarah Lewis, Danielle A. Griffin, Aaron Meadows, Kelly Lehman, Kathleen Church, Natalie Fae Miller, Megan Iammarino, Linda Pax Lowes, Jerry R. Mendell
4:32 p.m. ET S32.004
A Multicenter Randomized, Double-Blind, Placebo-Controlled, Gene-Delivery Clinical Trial of rAAVrh74.MHCK7.micro-dystrophin for Duchenne Muscular Dystrophy—Jerry R. Mendell, Perry Shieh, Zarife Sahenk, Kelly Lehman, Linda Pax Lowes, Natalie Fae Miller, Megan Iammarino, Lindsay N. Alfano, Jeremy Woods, Christy Skura, Howard Mao, Loretta Staudt, Rachael Potter, Danielle A. Griffin, Sarah Lewis, Tianle Hu, Sameer Upadhyay, Tejdip Singh, Louise R. Rodino-Klapac
4:40 p.m. ET S32.005
AAV Gene Therapy for TNNT1-associated Nemaline Myopathy—Eleonora D'Ambrosio, Monique Otero, Haley Grimason, Lena Labdi, Kevin Strauss, Heather Gray-Edwards, Miguel Esteves
4:48 p.m. ET
Questions and Answers
